Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.

"You guys make such a huge difference that you don't get credit for."

Mark Cuban on generic medicines.

View Video
GRx+Biosims 2023 Early Bird Discount

Save $100 when you register before May 31.

Register Now
ICYMI: See What Happened at Access! 2023

Follow updates on social media with hashtag #Access2023.

Follow AAM on Twitter
AAM’s Prescription for State Savings

State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.

Learn More
2021 Savings for Patients by Condition

Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. Learn more and download fact sheets about the savings by common patient conditions.

Read Blog
2022 U.S. Generic & Biosimilar Medicines Savings Report

Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.

View Report
Study Finds Middlemen Increasingly Block Patient Access to New Generics

New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.

Read Press Release
AAM Voices of Access

Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.

View Report
Who’s Profiting from Your Prescription?

Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Feb 15, 2023 | Susan Reilly

New Social Media Campaign Unveiled to Raise Awareness of the Essential Role of Generic Medicine in Americans’ Lives

Video

Feb 14, 2023 | Erica Klinger

A Fireside Chat with AAM Chair, Christine Baeder and Mark Cuban, Entrepreneur and Cost Plus founder.

Feb 13, 2023 | Susan Reilly

Christine Baeder Named Chair of the Association for Accessible Medicines Board of Directors

Feb 9, 2023 | Jonathan Kimball

The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites

Jan 30, 2023 | Susan Reilly

AAM Applauds CMS for Requiring Health Plans to Place Generic Drugs On Generic Tiers

Jan 26, 2023 | Erica Klinger

AAM Opposes HF17 and SF168 Which Won’t Bring Down Drug Prices for Minnesota Patients